Our Vision In Action
Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost
Our world-class drug discovery and development team is leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and pharmaceutical companies.
Program | DiscoveryPreclinicalPhase 1 | Rights |
---|---|---|
Rights Program SGR-1505 (MALT1)Relapsed /
Resistant![]() Non-Hodgkin's Lymphoma |
Phase 1
|
Schrödinger |
Program
SGR-2921 (CDC7)Hematological Cancers and Solid Tumors |
Phase 1
|
Schrödinger |
Program
SGR-3515 (Wee1)Gynecological Cancers and other Solid Tumors |
Discovery
|
Schrödinger |
Program LRRK2Neurology |
Discovery
|
Schrödinger |
Program Multiple Oncology Programs |
Discovery
|
Schrödinger |
Program Multiple Immunology Programs |
Discovery
|
Schrödinger |
Program | DiscoveryPreclinicalCLINICAL | Rights |
Rights
Program
SOS1 / KRASKRAS-Driven Cancers![]() ![]() |
Preclinical
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedOncology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedOncology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedImmunology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedNeurology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program Protein DegradersOncology,
Immunology and Neurology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Rights
Program UndisclosedOncology
![]() ![]() |
Discovery
|
Schrodinger and Takeda |
Rights
Program Undisclosed
![]() ![]() |
Discovery
|
Schrodinger and Lilly |
Rights

Rights






Collaborative Programs
We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials.
COLLABORATOR









Undisclosed
Undisclosed
Indication | DiscoveryPRECLINICALPHASE 1PHASE 2PHASE 3FDA APPROVED | COLLABORATOR |
---|---|---|
COLLABORATORINDICATION
![]() |
FDA APPROVED
|
|
COLLABORATORINDICATION
![]() |
FDA APPROVED
|
|
COLLABORATORINDICATION
![]() |
DISCOVERY
|
|
COLLABORATORINDICATION
![]() |
DISCOVERY
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Phase 2
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Phase 2
|
|
COLLABORATORINDICATION
![]() |
Phase 2
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Preclinical
|
|
COLLABORATORINDICATION
Undisclosed
Oncology
|
Phase 1
|
|
COLLABORATORINDICATION
Undisclosed
Undisclosed
|
Preclinical
|
* Acquired by Servier
** Acquired by Gilead